Mucocutaneous manifestations of inflammatory bowel disease in central China –a single‐centre study

Kou, Chun-Zhao; Zhang, Y.Y.; Li, G.W.; Li, J.; Kong, Qingtao; Chen, J.; Liu, F.; Zhang, M.; Wang, F.Y.; Jiang, Yuhang; Hao, Lijun; Ren, Jianan; Shi, Haiping

doi:10.1111/jdv.14720

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found that the prevalence of MCM in Greek IBD patients attending our referral center is 21.2%. This prevalence is in agreement with the reported range of that found in previous studies in the literature (2-53%) [2,[6][7][8][18][19][20][21]. The great variety in percentages of MCM could be attributed to the difficulty of accurate determination of MCM, use of different classification systems, inclusion/exclusion criteria, type of study (retrospective or prospective) and the expertise of the doctor who is doing the recruitment of patients with dermatological disorders, for example general practitioner, gastroenterologist or dermatologist.…”

Section: Discussionsupporting

confidence: 90%

“…Approximately one-third of patients with IBD have one or more extra-intestinal manifestation (EIM) [2]. Major dermatologic manifestations have been reported in 5–53% of IBD patients with some studies citing 22–75% in Crohn’s disease and 5–11% in ulcerative colitis [2–8. The prevalence of mucocutaneous manifestations (MCM) among IBD patients varies across the literature according to the definition used in each study.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mucocutaneous manifestations in patients with inflammatory bowel disease: a decade study from a Greek cohort

Koumaki

Machaira

Katoulis

et al. 2021

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background We sought to investigate the prevalence of mucocutaneous manifestations (MCM) and potential associations with clinical characteristics in Greek patients with IBD. Methods This was a retrospective observational single-center study. Patients with IBD diagnosis attending a tertiary referral hospital in Heraklion, Crete, from January 2010 to January 2020 were included. Data were extracted with relevant medical information from the IBD registry. Standard statistical tests, descriptive statistics tests, chi-square, Pearson correlation and multivariate analysis tests were performed, using IBM SPSS Statistics 25. Results A total of 806 IBD patients were included in the study: 463 (57.4%) males, 441 (54.7%) Crohn’s Disease, 352 (43.7%) ulcerative colitis and 13 (1.6%) IBD unclassified (IBD-U). Mean age was 50.67 ± 17.67 years, mean age of IBD diagnosis 36.67 ± 16.53 years and mean disease duration 13.65 ± 9.89 years. The prevalence of MCM was 171/806 (21.2%), 9.65% in ulcerative colitis and 30.84% in CD. The presence of MCM was significantly correlated with younger age of IBD diagnosis, longer IBD duration, CD diagnosis, inflammatory behavior and ileal or ileocolonic location of CD, extensive colitis in ulcerative colitis, intestinal manifestations (EIMs) and treatment with immunosuppressant or anti-TNFa. The development of MCM was independently associated with the presence of other EIMs odds ratio (OR), 4.03 [95% confidence interval (CI), 2.60–6.24; P < 0.001] and treatment with immunosuppressant (OR, 1.87; 95% CI, 01.14–3.07; P = 0.013) or anti-TNFa (OR = 2.47; 95% CI, 1.59–3.84; P < 0.01). Conclusions In our study, about one-fifth of IBD patients developed MCM that was more frequently present in CD than in ulcerative colitis.

show abstract